← Back to Home

Merck Secures SPR2015 with $400 Million Upfront, Betting on a New KRAS G12D-Targeted Drug

An oral drug candidate that has yet to enter human trials has secured a global licensing deal worth up to $2.13 billion. The investment adds resources to the KRAS G12D development race, but its performance in cell and animal studies remains a long way from becoming a treatment option for patients with pancreatic cancer.

By SURL BioNews

The promise of targeted therapies for pancreatic cancer is drawing major pharmaceutical companies into investments in earlier-stage research. Merck/MSD announced on September 28 that it had acquired exclusive global rights to SciBrunch Therapeutics’ drug candidate SPR2015. The oral drug, which targets the KRAS G12D mutation, remains in preclinical development. The deal represents a research and development bet, rather than evidence of efficacy in patients.

Under the terms announced by the companies, Merck will be responsible for the global development, manufacturing and commercialization of SPR2015. SciBrunch will receive a $400 million upfront payment, with additional milestone payments tied to progress in development, commercialization and other activities. The transaction has closed, with a potential total value of up to $2.13 billion, including the upfront payment; this ceiling does not mean that all payments have already been made.

SPR2015 is described as a “molecular glue” KRAS G12D (ON) inhibitor that targets the protein in its active state. G12D denotes a change in the amino acid at position 12 of KRAS from glycine to aspartic acid, which keeps signals promoting cell proliferation and survival continuously active. The core aim of the drug’s design is to interfere with this switch that drives cancer cell growth.

The evidence supporting this design currently comes from the laboratory. According to Merck’s announcement, SPR2015 inhibited proliferation in multiple cell lines carrying the KRAS G12D mutation and showed selectivity relative to wild-type cells without the mutation. Researchers also observed antitumor activity in animal xenograft models derived from cancer cells and patient tumors. The findings were presented at the 2026 American Association for Cancer Research Annual Meeting. Even when models use patient tumor tissue, their results cannot be regarded as outcomes in patients who have received treatment.

Background

The deal also reflects considerations surrounding Merck’s own product portfolio. Dow Jones Newswires placed it in the context of Keytruda’s expected loss of patent protection in 2028 and the company’s efforts to strengthen its pipeline of subsequent products. From this perspective, SPR2015 is both an investment in a KRAS-targeting strategy and an addition to the company’s future oncology portfolio of drug candidates. Whether an early-stage asset can become an approved drug in time, however, remains highly uncertain.

For the treatment of cancers such as pancreatic cancer, the next hurdle is human research: whether the drug can reach tumors at tolerable doses, sustain target inhibition and deliver meaningful clinical benefit. This announcement provided no human safety, tumor response or survival data, nor did it specify a timeline for starting the first human trial. Funding and global development capabilities are now in place, while the question of efficacy still awaits answers from clinical trials.

References

  1. finance.biggo.com
  2. Merck & Co., Inc.
  3. Dow Jones Newswires via MarketScreener